Efficacy of BEZ235 on objective response rate according to RECIST 1.1
ID
Source
Brief title
Condition
- Soft tissue neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Objective response according to RECIST 1.1.
Secondary outcome
Progression free survival
Duration of response
Time to response
Time to progression
Overall survival
Safety and tolerability of BEZ235
Background summary
This study investigates whether BEZ235 will slow the growth of PEComa tumors.
Also, the study will explore the side effect of BEZ235. BEZ235 is an PI3K- and
mTOR inhibitor possibly slowing the growth of tumor cells.
Study objective
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
Study design
Multicenter, prospective, non-randomized, open-label, single arm phase II study
in two phases.
Intervention
BEZ235 medication
Study burden and risks
The visit frequency is not much higher than normal clinical practise except for
the first 8 months. Blood draw is larger than normal but not excessive.
Raapopseweg 1
Arnhem 6824 DP
NL
Raapopseweg 1
Arnhem 6824 DP
NL
Listed location countries
Age
Inclusion criteria
Histologically confirmed diagnosis of malgnant PEComa (included epithelioid angiomyolipoma (AML) in adult patients
Unresectable/advanced and/ or metastatic and documented progressive measurable disease
Treated with 1 or 2 prior lines of treatment
Exclusion criteria
Disease exclusions: Lymphangioleiomyomatosis (LAM) exclusively
Active uncontrolled or symptomatic CNS metastases, concurent malignancy or malignancy in last three years.
Concurrent severe and/or uncontrolled medical condition (for details see protocol)
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2011-001884-39-NL |
CCMO | NL42047.058.12 |